文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

新型经导管二尖瓣置换术首100例可行性研究

Initial Feasibility Study of a New Transcatheter Mitral Prosthesis: The First 100 Patients.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

全球可行性研究纳入首批100例有症状的原发性或继发性二尖瓣反流且外科高危或禁忌患者,接受新型经导管二尖瓣置换术。技术成功率96%,30天死亡率和卒中率分别为6%和2%,1年无全因死亡生存率72.4%。器械有效减轻二尖瓣反流并改善症状,安全性可接受,需进一步研究优化长期生存。

要点

  • 技术成功率达96%,无术中死亡,无急性转外科或需体外循环。
  • 30天死亡率和卒中率分别为6%和2%,1年无全因死亡生存率72.4%。
  • 1年存活者中88.5%为NYHA I/II级,6分钟步行距离和生活质量显著改善。

核心结论

  • 该新型经导管二尖瓣置换器械能高效减轻二尖瓣反流并改善症状,安全性可接受。
  • 需进一步研究以优化对长期生存的影响。

研究设计与样本

  • 全球可行性研究,分析首批100例接受新型经导管二尖瓣置换术的患者。
  • 纳入有症状的原发性或继发性二尖瓣反流且外科高危或禁忌的患者。
  • 平均年龄75.4±8.1岁,69%为男性,平均射血分数46.4±9.6%,STS预测死亡率7.8±5.7%。

主要发现

  • 无术中死亡,1例重大心尖出血,无急性转外科或需体外循环,技术成功率96%。
  • 30天死亡率和卒中率分别为6%和2%。
  • 1年无全因死亡生存率72.4%(95%CI:62.1%至80.4%),其中84.6%的死亡为心源性。
  • 1年存活者中88.5%为NYHA I/II级,6分钟步行距离改善(p<0.0001),生活质量改善(p=0.011)。
  • 73.4%的存活者KCCQ评分改善≥10分。

临床怎么用

  • 对于外科高危或禁忌的原发性或继发性二尖瓣反流患者,该经导管二尖瓣置换器械可作为可行治疗选择。
  • 术后1年多数存活者心功能和生活质量显著改善,但需关注心源性死亡风险。

局限性

  • 随访时间和治疗例数有限。
  • 需进一步研究优化长期生存影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter mitral valve replacement (TMVR) is a rapidly evolving therapy. Follow-up of TMVR patients remains limited in duration and number treated. OBJECTIVES: The purpose of this study was to examine outcomes with expanded follow-up for the first 100 patients who underwent TMVR with the prosthesis. METHODS: The Global Feasibility Study enrolled symptomatic patients with either primary or secondary mitral regurgitation (MR) who were at high or prohibitive surgical risk. The present investigation examines the first 100 patients treated in this study. Clinical outcomes through last clinical follow-up were adjudicated independently. RESULTS: In the cohort (mean age 75.4 ± 8.1 years; 69% men), there was a high prevalence of severe heart failure symptoms (66%), left ventricular dysfunction (mean ejection fraction 46.4 ± 9.6%), and morbidities (Society of Thoracic Surgeons Predicted Risk of Mortality, 7.8 ± 5.7%). There were no intraprocedural deaths, 1 instance of major apical bleeding, and no acute conversion to surgery or need for cardiopulmonary bypass. Technical success was 96%. The 30-day rates of mortality and stroke were 6% and 2%, respectively. The 1-year survival free of all-cause mortality was 72.4% (95% confidence interval: 62.1% to 80.4%), with 84.6% of deaths due to cardiac causes. Among survivors at 1 year, 88.5% were New York Heart Association function class I/II, and improvements in 6-min walk distance (p < 0.0001) and quality-of-life measurements occurred (p = 0.011). In 73.4% of survivors, the Kansas City Cardiomyopathy Questionnaire score improved by ≥10 points. CONCLUSIONS: In this study of TMVR, which is the largest experience to date, the prosthesis was highly effective in relieving MR and improving symptoms, with an acceptable safety profile. Further study to optimize the impact on long-term survival is needed.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sorajja P, Moat N, Badhwar V, et al. Initial Feasibility Study of a New Transcatheter Mitral Prosthesis: The First 100 Patients. J Am Coll Cardiol. 2019. PMID: 30898200. doi:10.1016/j.jacc.2018.12.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。